| 2.135 -0.025 (-1.16%) | 10-16 10:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.89 | 1-year : | 3.37 |
| Resists | First : | 2.47 | Second : | 2.89 |
| Pivot price | 1.77  |
|||
| Supports | First : | 1.48 | Second : | 0.87 |
| MAs | MA(5) : | 2.15 |
MA(20) : | 1.57 |
| MA(100) : | 1.56  |
MA(250) : | 2.02 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 76.9 |
D(3) : | 77.8 |
| RSI | RSI(14): 69.2 | |||
| 52-week | High : | 4.3 | Low : | 0.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NAUT ] has closed below upper band by 25.1%. Bollinger Bands are 128.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.21 | 2.21 - 2.22 |
| Low: | 1.88 - 1.9 | 1.9 - 1.91 |
| Close: | 2.14 - 2.16 | 2.16 - 2.18 |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Thu, 15 Oct 2026
Nautilus Biotechnology to Report Third Quarter 2026 Financial Results on October 27 - Quiver Quantitative
Thu, 15 Oct 2026
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 - Yahoo Finance UK
Wed, 14 Oct 2026
symbol__ Stock Quote Price and Forecast - CNN
Fri, 02 Oct 2026
NAUT Stock Climbs As Wall Street Backs Voyager Platform - StocksToTrade
Mon, 21 Sep 2026
Nautilus Biotechnology, Inc. SEC Filing (Sep 21, 2026) - Stock Titan
Fri, 28 Aug 2026
Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 127 (M) |
| Held by Insiders | 6.747e+007 (%) |
| Held by Institutions | 32 (%) |
| Shares Short | 3,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.135e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 296.3 % |
| Return on Equity (ttm) | -20.9 % |
| Qtrly Rev. Growth | 190000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -49.61 |
| EBITDA (p.s.) | 239726 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.53 |
| Dividend | 0 |
| Forward Dividend | 5.77e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|